Kavita Vinod Paul: Transforming Lives Through Comprehensive Care and Community Leadership
Kavita Vinod Paul, National Sales Head at Novo Nordisk, shared a post on LinkedIn:
“I had the opportunity to meet Dr. Maganti BSV Prasad and team, whose unwavering commitment has transformed the lives of thousands of individuals living with hemophilia, thalassemia, sickle cell disease, von Willebrand disease, and other inherited blood disorders.
As the driving force behind the Hemophilia Society, Vijayawada Chapter – Eluru, Dr. Prasad has built far more than a patient support organization – he has created a legacy of compassionate care, early diagnosis, quality diagnostics, patient education, genetic counselling, physiotherapy, psychosocial support, and community empowerment that has touched three generations of patients and families.
What inspired me even more was the Society’s commitment to nurturing future leaders. Under Dr. Prasad’s guidance, the organization has mentored and inspired:
- 1 MD Radiologist
- 4 MBBS students
- 3 IIT graduates
- 3 PhD scholars
- 2 Chartered Accountants
- 3 NIT graduates
- 2 IIIT graduates
- 100 and more IT professionals
- 30 and more professionals serving in Government Services
This extraordinary contribution demonstrates that patient organizations can create an impact far beyond healthcare – empowering individuals, building careers, and inspiring generations of professionals committed to giving back to society.
The Hemophilia Society, Vijayawada Chapter, in collaboration with the Indian Red Cross Society, Eluru District Branch, is a remarkable example of how vision, partnerships, and selfless leadership can improve access to comprehensive care while creating lasting social impact.
My sincere gratitude to Dr. Maganti BSV Prasad and the entire team for their warm hospitality and for reminding us that true leadership is measured not only by the lives we heal but also by the lives we inspire.
Thank you Singa Reddy for the opportunity!”
Stay updated with Hemostasis Today.
-
Aug 6, 2026, 18:11Filipe Gonçalves: Are DOACs Truly Pharmacokinetically Predictable or Simply Pharmacodynamically Forgiving?
-
Aug 6, 2026, 18:04Wolfgang Miesbach: Base Editing Expands Therapeutic Targets for Hemophilia B
-
Aug 6, 2026, 18:03Identifing Gaps in How IDA is Recognised and Managed in Children – ISBT
-
Aug 6, 2026, 18:03Expanding Access to Care for People With Hemophilia in Côte d’Ivoire – WFH
-
Aug 6, 2026, 17:59BSH Good Practice Paper on Multidisciplinary Hematology and Gynecology Care – British Journal of Haematology
-
Aug 6, 2026, 17:38Cameron Cook: How Cost-Effective Is Evolocumab for Patients at High Cardiovascular Risk?
-
Aug 6, 2026, 15:53Pall T. Onundarson: Frail Elderly Korean Atrial Fibrillation Patients Do Worse If Switched to DOACs in a Nationwide Observational Study
-
Aug 6, 2026, 15:46Zain Khalpey: Left Atrial Appendage Closure vs Oral Anticoagulation in Atrial Fibrillation
-
Aug 6, 2026, 15:25Mohd Ashhad: Cryoprecipitate – A Small Blood Component with a Big Clinical Role